Theodore R. Schroeder - 06 Jun 2022 Form 4 Insider Report for Nabriva Therapeutics plc (NBRVF)

Role
Chief Executive Officer, Director
Signature
/s/ J. Christopher Naftzger, by power of attorney
Issuer symbol
NBRVF
Transactions as of
06 Jun 2022
Transactions value $
-$45
Form type
4
Date filed
07 Jun 2022, 16:47
Previous filing
02 Jun 2022
Next filing
23 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBRVF Ordinary Shares Tax liability -$45 -225 -0.07% $0.20 313K 06 Jun 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units.